PAX5 point mutations have been identified in 7–10% of pediatric cases of B-ALL, similar to the frequency in our patients (7.3%), being the second most common PAX5 type of alteration. This evidence concerns the gene PAX5 and precursor B-cell acute lymphoblastic leukemia.